Company intelligence / Profile preview

KORTUC Inc.

Palo Alto, California, USAkortuc.com ↗

Ownership: Private
Development stage: Phase 2

Overview

KORTUC's radiosensitizer has shown significant efficacy in clinical investigations for breast cancer with reported 99% efficacy (71/72 patients). A Phase 2/3 registrational study is ongoing in the UK for locally advanced/recurrent breast cancer. The product has been used in over 1,000 patients in Japan in investigator-initiated clinical research with no major safety concerns reported.[5][7]

Therapeutic areas: Oncology
Modalities: Radiosensitizer (hydrogen peroxide-based)
Industry: Biotech

Drug pipeline

2 assets

KRC-01

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on KORTUC Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KORTUC Inc..

Explore the full profile